Skip to main content

Clinical significance of hyperbilirubinemia in the CASTLE study

Purpose of the study

While unconjugated hyperbilirubinemia is associated with the use of ritonavir-boosted atazanavir (ATV/r), the nature of the hyperbilirubinemia over time and its clinical significance has not been well-characterized in controlled studies. The purpose of this study is to describe the patterns and clinical significance of hyperbilirubinemia in patients treated with ATV/r in the CASTLE study.

Methods

CASTLE was a randomized, 96-week study to assess the efficacy and safety of ATV/r vs. lopinavir/r, each with tenofovir/emtricitabine, in treatment-naïve patients. This analysis included only ATV/r patients. The proportions of patients with hyperbilirubinemia (grades 3-4 total bilirubin elevation) were tabulated for each study visit. The impact of hyperbilirubinemia on symptoms (jaundice or scleral icterus), ASL/ALT elevations, quality of life (MOS-HIV physical and mental summary scores), and adherence (MACS adherence questionnaire) were described.

Summary of results

Although the proportion of patients with hyperbilirubinemia at any time throughout the study was 44%, the proportion of ATV/r patients with hyperbilirubinemia at any single visit was between 12.5% and 21.6%. Of patients with hyperbilirubinemia at any time, 11% had grades 2-4 treatment-related jaundice or scleral icterus at any time (0 of patients without hyperbilirubinemia), and 4% had grades 3-4 AST/ALT elevations at any time (3% of patients without hyperbilirubinemia). Quality of life and adherence in patients without and with hyperbilirubinemia. Table 1.

Table 1

Conclusions

Hyperbilirubinemia, while common in patients on ATV/r at any time through 96 weeks in the CASTLE study, was less frequent at any single time point and not associated with related symptoms in most patients. The presence of hyperbilirubinemia did not affect AST/ALT elevations, quality of life, or adherence. These data suggest that hyperbilirubinemia observed with ATV/r does not impact clinical outcomes.

Author information

Authors and Affiliations

Authors

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Uy, J., Hu, W., Wirtz, V. et al. Clinical significance of hyperbilirubinemia in the CASTLE study. JIAS 13, P93 (2010). https://doi.org/10.1186/1758-2652-13-S4-P93

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1758-2652-13-S4-P93

Keywords

  • Clinical Outcome
  • Clinical Significance
  • Bilirubin
  • Total Bilirubin
  • Summary Score